Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Market Events Policy Update | OpenP…
    Ask Trek AI about this page
    CurrentVentura County Health Care PlanPolicy N/A

    Market Events Criteria

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs pharmacy utilization-management and step-therapy requirements for selected branded, non-formulary, dosage-form, combination, specialty, and other targeted medications. Approval generally requires documented trials, intolerance, inadequate efficacy, contraindication, formulation-related medical necessity, or a significant clinical concern preventing use of the preferred alternative.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyMarket Events Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJanuary 15, 2026
    Last ReviewOct 29, 2025
    Next Review DateN/A
    Key ActionDocument the products tried, relevant treatment history, clinical response, and any intolerance, inadequate efficacy, contraindication, or clinical exception supporting the request.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5Unique prescription-strength oral NSAIDs required
    1 yearCommon approval duration
    130 daysGeneric sacubitril-valsartan look-back period
    2Alternative products required for selected trials

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    N/ADuration for explicitly non-covered medications

    Product-Specific Coverage Criteria

    Topical corticosteroid and anti-infective therapy

    Covered when all of the following are met:

    Topical therapy failure: The patient has tried five single-entity topical corticosteroids and one prescription topical anti-infective, with inadequate efficacy or significant intolerance according to the prescriber.5 corticosteroids + 1 anti-infective

    Examples include hydrocortisone, betamethasone, clobetasol, fluocinolone, fluocinonide, mometasone, triamcinolone, and mupirocin.

    Five-NSAID step therapy

    Covered when the patient meets the NSAID step-therapy requirement:

    NSAID trials: The patient has tried five unique prescription-strength oral NSAIDs.5 unique NSAIDs

    OTC NSAIDs count only when used at prescription-strength doses. Five unique NSAIDs means five different NSAID products; examples include nabumetone, etodolac, flurbiprofen, ibuprofen, ketoprofen, meloxicam, naproxen, oxaprozin, diclofenac, piroxicam, and indomethacin.

    Antihistamine criteria

    Covered when both parts of the antihistamine sequence are satisfied:

    Antihistamine failure or intolerance

    • ONE of the first agents: The patient has tried loratadine, fexofenadine, or cetirizine and experienced inadequate efficacy or significant intolerance.
    • Chlorpheniramine: The patient has also tried chlorpheniramine and experienced inadequate efficacy or significant intolerance.

    Antihistamine dosage-form criteria

    Covered when one of the following dosage-form pathways applies:

    Antihistamine dosage-form pathway

    • Standard oral pathway: The patient has tried five oral antihistamines.5 oral antihistamines

      Examples include clemastine tablets, diphenhydramine, chlorpheniramine, carbinoxamine, hydroxyzine, and cetirizine.

    • Liquid pathway: The patient is unable to swallow or has difficulty swallowing tablets and has tried at least two of the following: carbinoxamine syrup, diphenhydramine solution, or hydroxyzine solution or syrup.2 liquid antihistamines

    Hydroxyurea criteria

    Covered when one of the following hydroxyurea pathways applies:

    Hydroxyurea pathway

    • Trial or current use: The patient has tried or is currently receiving one hydroxyurea product, including hydroxyurea, Droxia, or Siklos.1 hydroxyurea product

      A patient who has already tried or is currently taking one hydroxyurea product is not required to try another.

    • Formulary exception: None of the hydroxyurea products are formulary.
    • Clinical exception: The prescriber states that the patient is not a candidate for hydroxyurea, such as because of planned pregnancy, pregnancy, or an immunosuppressive condition such as cancer.

    Extended-release amantadine criteria

    Covered when the patient has first tried immediate-release amantadine and meets one of the following response pathways:

    Immediate-release prerequisite

    • Trial: The patient has tried immediate-release amantadine in a capsule, tablet, or oral solution.
    • ONE of the following

      • Intolerable adverse events: The patient derived benefit from immediate-release amantadine but had intolerable adverse events, as determined by the prescriber.
      • Insufficient dose response: The patient could not achieve a high enough dosage to gain adequate benefit, as determined by the prescriber.

    Levorphanol and Librax criteria

    Covered when the applicable product-specific prerequisites are met:

    Levorphanol prerequisites: The patient has tried three opioid products from different groups, selected from morphine-, hydrocodone-, hydromorphone-, oxycodone-, oxymorphone-, fentanyl-, methadone-, or tapentadol-containing products.3 products from different opioid groups

    Librax prerequisites

    • Required trials: The patient has tried both a dicyclomine-containing product and a hyoscyamine-containing product.Both products

      Eligible dicyclomine dosage forms include tablet, capsule, or syrup; eligible hyoscyamine forms include tablet or solution.

    • Existing therapy: The patient has already been started on chlordiazepoxide-clidinium.

    Brand and inactive-ingredient exceptions

    Covered when the prescriber documents the applicable brand or inactive-ingredient exception:

    Brand or formulation exception

    • Inactive-ingredient exception: The requested brand has an inactive-ingredient difference from the bioequivalent generic, such as a difference in dyes, fillers, or preservatives, that would cause a significant allergy or serious adverse reaction, according to the prescriber.
    • Pregnancy or birth-outcome exception: For prevention of pregnancy or improvement of birth outcomes, the prescriber states that the preferred bioequivalent generic would not be medically appropriate.
    Niacin exception: The patient has tried and cannot take at least two other prescription or OTC niacin-containing products because of a significant inactive-ingredient allergy or significant adverse reactions, and the physician documents the relevant ingredient differences or serious reactions.2 niacin products

    Oxycodone-acetaminophen criteria

    Covered when one of the following oxycodone-acetaminophen pathways applies:

    Preferred strength or dosage-form exception

    • Tablet strength exception: The patient has tried the corresponding oxycodone-acetaminophen 325 mg tablet and the prescriber documents a significant clinical concern preventing its use.

      The corresponding preferred strengths are 10-325 mg, 2.5-325 mg, 5-325 mg, or 7.5-325 mg tablets for the requested 300 mg acetaminophen strength.

    • Oral solution exception: For the 300/5 oral solution, the patient is unable to swallow or has difficulty swallowing tablets.

    Target test-strip criteria

    Covered when one of the following target test-strip pathways applies:

    Test-strip pathway

    • Alternative strip trial: The patient has tried one of the listed alternative test strips, such as Freestyle, Freestyle Lite, Freestyle Insulinx, Precision Xtra, TRUE METRIX, TRUEtrack, or another Trividia/Nipro test strip.1 alternative strip
    • Device compatibility exception: The patient uses an insulin pump or meter system that is not compatible with the listed alternative test strips.
    • Visual-impairment exception: The prescriber documents significant visual impairment supporting use of a National Medical/Diabetic Supply or Omnis Health test strip, such as Advocate Redi-Code or Embrace.

    Triptan criteria

    Covered when one of the following triptan pathways applies:

    Triptan pathway

    • Generic nasal-spray trial: The patient has tried one generic triptan nasal spray, such as sumatriptan or zolmitriptan nasal spray.1 generic triptan nasal spray
    • Failure or contraindication: The patient has experienced inadequate efficacy or a contraindication with a triptan product.

    Amlodipine 10 mg–celecoxib 200 mg solution is not covered under Market Events. The product record lists an approval duration of N/A; prerequisite trials displayed elsewhere in the criteria do not create coverage for this solution.

    Indocin (indomethacin) 50 mg suppository is not covered under Market Events. An approval exception applies when the patient has tried ibuprofen suspension or naproxen suspension; if neither product is formulary, approval may be granted. OTC ibuprofen suspension counts toward the trial requirement. The listed approval duration is N/A.

    Lidocaine-tetracaine 7%/7% cream is not covered under Market Events. The listed approval duration is N/A.

    Lorzone (chlorzoxazone) 375 mg tablets are not covered under Market Events. The listed approval duration is N/A.

    Trinaz tablets, identified as a prescription dietary supplement for use throughout pregnancy, are not covered under Market Events. The listed approval duration is N/A.

    Prescriber Requirements and Decision Rules

    Step Therapy

    Fluticasone-Salmeterol or Wixela Trial

    Approve when the patient has tried fluticasone-salmeterol inhalation powder (generic Advair Diskus) or Wixela Inhub. Documentation of the qualifying trial is required.

    • Qualifying products: fluticasone-salmeterol inhalation powder or Wixela Inhub.
    • Document the product tried and treatment outcome.
    Step Therapy

    Topical Corticosteroid and Anti-Infective Trials

    Approve when the patient has tried five single-entity topical corticosteroids and one prescription topical anti-infective, with inadequate efficacy or significant intolerance documented by the prescriber.

    • Examples of topical corticosteroids include hydrocortisone, betamethasone, clobetasol, fluocinolone, fluocinonide, mometasone, and triamcinolone products.
    • Examples of prescription topical anti-infectives include mupirocin cream or ointment, Centany, Centany AT, and Altabax.
    • Document each product tried and the inadequate response or intolerance.

    Policy Terms and Operational Definitions

    Five Unique NSAIDs
    DefinitionFive unique NSAIDs means five different NSAID products.
    Required trialApplicable products require five prescription-strength oral NSAID trials.
    OTC qualificationOver-the-counter NSAIDs count only when used at prescription-strength doses.
    Multisource Brand
    DefinitionA multisource brand is a brand product with a bioequivalent generic alternative.
    Preferred productThe patient should use the preferred bioequivalent generic product.
    Documentation expectation

    Initial Authorization Decision Framework

    Product-specific initial authorization

    Initial approval requires the applicable product-specific prerequisite, exception, or documented clinical rationale:

    Applicable product-specific pathway

    • Required prerequisite trial: The patient has completed the prerequisite trial or sequence specified for the requested product, such as required alternative medications, preferred strengths, dosage forms, or products from specified therapeutic groups.
    • Formulary exception: The required preferred alternative is non-formulary or unavailable when the product-specific criterion permits approval on that basis.
    • Inadequate efficacy or intolerance: The prescriber documents inadequate efficacy or significant intolerance with the required preferred alternative or trial products.

    Required Preferred-Product Sequences

    Requested productRequired stepException or approval pathway
    Applicable antihistamine productTry five oral antihistamines, such as clemastine, diphenhydramine, chlorpheniramine, carbinoxamine, hydroxyzine, or cetirizine.If the patient cannot swallow or has difficulty swallowing tablets, try at least two of carbinoxamine syrup, diphenhydramine solution, or hydroxyzine solution or syrup.
    Requested productRequired stepException or approval pathway
    Products subject to NSAID step therapyTry five unique prescription-strength oral NSAIDs. OTC NSAIDs count when used at prescription-strength doses.Document the trials and clinical response, including prescription-strength dosing when an OTC NSAID was used.
    Requested productRequired stepException or approval pathway
    Hydroxyurea-related therapyTry or currently use one hydroxyurea product, including hydroxyurea, Droxia, or Siklos.Approval may be granted if no hydroxyurea product is formulary or the prescriber documents that the patient is not a candidate, such as for planned pregnancy, pregnancy, or an immunosuppressive condition. One prior or current product is sufficient.
    Requested productRequired stepException or approval pathway
    Gocovri or Osmolex extended-release amantadineTry immediate-release amantadine capsules, tablets, or oral solution.The patient must have benefited but experienced intolerable adverse events, or been unable to reach a high enough dose for adequate benefit, as determined by the prescriber.
    Requested productRequired stepException or approval pathway
    Levorphanol 2 mg or 3 mg tabletsTry three opioid products from different groups, selected from morphine-, hydrocodone-, hydromorphone-, oxycodone-, oxymorphone-, fentanyl-, methadone-, or tapentadol-containing products.Document inadequate response or intolerance to the required products or groups.
    Requested productRequired stepException or approval pathway
    Oxycodone-acetaminophen 10-300, 2.5-300, 5-300, or 7.5-300 tabletsUse the corresponding 325 mg tablet: 10-325, 2.5-325, 5-325, or 7.5-325 mg.Approve when the prescriber documents a significant clinical concern preventing use of the corresponding 325 mg tablet. For the 300/5 oral solution, approval may be granted when the patient cannot swallow or has difficulty swallowing tablets.
    Requested productRequired stepException or approval pathway
    Target Lifescan blood glucose test stripsTry one alternative strip, such as Freestyle, Freestyle Lite, Freestyle Insulinx, Precision Xtra, TRUE METRIX, TRUEtrack, or another Trividia/Nipro strip.Approval may be granted when the insulin pump or meter is incompatible with the alternatives, or when significant visual impairment supports a National Medical/Diabetic Supply or Omnis Health strip, such as Advocate Redi-Code or Embrace.
    Requested productRequired stepException or approval pathway
    Applicable triptan nasal-spray productTry one generic triptan nasal spray, such as sumatriptan or zolmitriptan nasal spray.Approval may be granted when the patient has experienced inadequate efficacy or a contraindication with a triptan product.
    Requested productRequired stepException or approval pathway
    Venlafaxine ER tabletsUse venlafaxine ER capsules before ER tablets.Approve 225 mg ER tablets; approve other tablet strengths if capsules are non-formulary or the prescriber documents a significant clinical concern preventing capsule use.
    Requested productRequired stepException or approval pathway
    Brand Vyvanse capsulesTry generic lisdexamfetamine capsules first.Document the generic trial and its inadequate efficacy, intolerance, or other clinical reason it is not suitable.
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyMarket Events Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJanuary 15, 2026
    Last ReviewOct 29, 2025
    Next Review DateN/A
    Key ActionDocument the products tried, relevant treatment history, clinical response, and any intolerance, inadequate efficacy, contraindication, or clinical exception supporting the request.
    SourceLink
    On This Page
    Product-Specific Coverage CriteriaPrescriber Requirements and Decision RulesPolicy Terms and Operational DefinitionsInitial Authorization Decision FrameworkRequired Preferred-Product Sequences

    Applies to Niacor 500 mg tablets.

    Documentation Required

    Preferred Formulation or Strength Exceptions

    Direct the patient to the preferred formulation, strength, dosage form, or bioequivalent generic first. Approve a non-preferred product only when the required substitution is not appropriate and the prescriber documents the qualifying clinical exception.

    • Direct to the preferred strength or formulation when available.
    • For multisource brands, document an inactive-ingredient difference such as dyes, fillers, or preservatives that causes a significant allergy or serious adverse reaction.
    • Document the requested product, the preferred alternative, and the clinical impact of substitution.
    Prior Authorization

    Chlorzoxazone Strength and Swallowing Exception

    Direct chlorzoxazone requests to 500 mg tablets. Approve 250 mg only when the prescriber documents a significant clinical concern preventing use of the 500 mg tablets; if the 500 mg tablets are unavailable, allow a one-time override.

    • For swallowing difficulty, the 250 mg direction may be considered when the patient cannot swallow or has difficulty swallowing tablets.
    • Document the clinical concern or swallowing limitation.
    Step Therapy

    Antihistamine Step Therapy

    Approve antihistamine step therapy when the patient has tried loratadine, fexofenadine, or cetirizine and chlorpheniramine, with inadequate efficacy or significant intolerance documented by the prescriber.

    • Prescription or over-the-counter products count.
    • When tablets cannot be swallowed, approve after trials of at least two of carbinoxamine syrup, diphenhydramine solution, or hydroxyzine solution or syrup.
    • Document the products tried and the response or intolerance.
    Step Therapy

    Five-NSAID Requirement

    Approve after five unique prescription-strength oral NSAID trials are documented. Prescription or over-the-counter products count when prescription-strength doses were used.

    • Examples include nabumetone, etodolac, flurbiprofen, ibuprofen, ketoprofen, meloxicam, naproxen, oxaprozin, diclofenac, piroxicam, and indomethacin.
    • The five trials must be unique NSAIDs.
    • Document each product, dose or strength, treatment history, response, and intolerance.
    Step Therapy

    Sacubitril-Valsartan Prerequisite

    Approve Entresto only after a trial of generic sacubitril-valsartan tablets is documented, unless the patient has a generic sacubitril-valsartan claim within the 130-day look-back period identified by automation.

    • The requested Entresto product does not itself satisfy the prerequisite.
    • Review claims history for generic sacubitril-valsartan within 130 days.
    Step Therapy

    Hydroxyurea Product Requirement

    Approve when the patient has tried or is currently receiving one hydroxyurea product. A prior trial or current use of hydroxyurea, Droxia, or Siklos satisfies the requirement.

    • If one hydroxyurea product has already been tried or is currently used, do not require another hydroxyurea agent.
    • Approve when no hydroxyurea product is formulary.
    • Approve when the prescriber documents that the patient is not a candidate, such as pregnancy planning, pregnancy, or an immunosuppressive condition.
    Step Therapy

    Amantadine Extended-Release Criteria

    Approve Gocovri or Osmolex extended-release amantadine after a trial of immediate-release amantadine capsules, tablets, or oral solution and documentation of a qualifying clinical reason.

    • Qualifying reasons: benefit from immediate-release therapy with intolerable adverse events, or inability to reach an effective dose with immediate-release therapy.
    • The prescriber must document the response and adverse-effect or dosing limitation.
    Step Therapy

    Indomethacin Suppository Step Therapy

    Indomethacin suppository requests require a trial of ibuprofen suspension or naproxen suspension. Approve when neither alternative is formulary.

    • Over-the-counter ibuprofen suspension counts as an alternative.
    • The requested indomethacin suppository does not replace the required suspension trial.
    • Document the trial or the formulary exception.
    Step Therapy

    Ketoprofen Prerequisite

    Approve ketoprofen only after a trial of lactulose oral solution, unless lactulose oral solution is non-formulary.

    • The trial must be of lactulose solution for oral administration.
    • Document the trial or non-formulary status.
    Step Therapy

    Levorphanol Opioid Trials

    Approve levorphanol after trials of three opioid products from different opioid groups.

    • Groups may include morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, fentanyl, methadone, or tapentadol products.
    • Document the three distinct products, treatment history, response, and intolerance.
    Step Therapy

    Librax Prerequisite Therapy

    Approve Librax when the patient has tried both a dicyclomine-containing product and a hyoscyamine-containing product, or when the patient has already been started on chlordiazepoxide-clidinium.

    • Dicyclomine products may be tablets, capsules, or syrup.
    • Hyoscyamine products may be tablets or solution.
    • Document both prerequisite therapies or the existing Librax-related treatment.
    Step Therapy

    Topical Hemorrhoidal Product Criteria

    Approve the topical hemorrhoidal product after trials of both hydrocortisone acetate 2.5%-pramoxine 1% cream and lidocaine 3%-hydrocortisone acetate 0.5% cream. An ingredient allergy or intolerance may support an exception when the requested product omits that ingredient.

    • Document both required products and the response.
    • For an allergy or intolerance exception, identify the offending ingredient and explain why it is absent from the requested product.
    Documentation Required

    Niacin Product Exception

    Approve Niacor when the patient has tried and cannot take at least two other prescription or over-the-counter niacin-containing products because of a significant inactive-ingredient allergy or significant adverse reactions.

    • Document the two products tried.
    • For an inactive-ingredient allergy, identify the relevant difference in dyes, fillers, or other ingredients.
    • For adverse reactions, document the serious reaction and clinical concern.
    Step Therapy

    Orphenadrine Combination Prerequisite

    Approve Orphengesic Forte or another orphenadrine-aspirin-caffeine combination after trials of prescription orphenadrine citrate extended-release 100 mg and an over-the-counter aspirin-and-caffeine product.

    • Examples of OTC products include Anacin, Bayer Back and Body Pain, and BC Arthritis.
    • Documentation is required for both trials.
    Step Therapy

    Novacort Topical Trial Requirement

    Approve Novacort after trials of four listed products, with inadequate efficacy or significant intolerance documented by the prescriber. Approve if none of the alternatives are formulary.

    • Qualifying products: Epifoam, hydrocortisone-pramoxine cream, Pramosone cream, Pramosone lotion, and Pramosone ointment.
    • The four products must be selected from this list.
    • Document each trial and the clinical response or intolerance.
    Documentation Required

    Brand Non-Formulary Exception

    A multisource brand should be replaced by its preferred bioequivalent generic. Approve the brand when the prescriber documents that an inactive-ingredient difference causes a significant allergy or serious adverse reaction.

    • Identify the inactive-ingredient difference, such as dyes, fillers, or preservatives.
    • Explain the resulting allergy or serious adverse reaction and why the generic is not appropriate.
    • For applicable preventive or birth-outcome coverage, document why the generic is not medically appropriate.
    Prior Authorization

    Oxycodone-Acetaminophen Dosage-Form Criteria

    Direct oxycodone-acetaminophen 10-300, 7.5-300, 5-300, or 2.5-300 mg tablets to the corresponding 325 mg formulation. Approve an exception when the prescriber documents a significant clinical concern preventing use of the 325 mg product.

    • 10-300 mg directs to 10-325 mg.
    • 7.5-300 mg directs to 7.5-325 mg.
    • 5-300 mg directs to 5-325 mg.
    • 2.5-300 mg directs to 2.5-325 mg.
    • For Prolate 10-300 mg tablets, document a trial and inability to take 10-325 mg tablets.
    Documentation Required

    Blood Glucose Test-Strip Criteria

    Approve target glucose test strips after a trial of one qualifying alternative strip, unless the patient uses an incompatible insulin pump or meter system or has significant visual impairment requiring an alternative supply.

    • Qualifying alternatives include Freestyle, Freestyle Lite, Freestyle Insulinx, Precision Xtra, TRUE METRIX, TRUEtrack, or another Trividia/Nipro strip.
    • For pump or meter incompatibility, document the system and incompatibility.
    • For visual impairment, document the prescriber's assessment; National Medical/Diabetic Supply or Omnis Health strips may qualify.
    Step Therapy

    Treximet Prerequisite Therapy

    Approve Treximet after trials of both naproxen and sumatriptan tablets. A trial of Treximet itself does not satisfy the prerequisite.

    • Sumatriptan may include Imitrex or generic tablets.
    • Document both component-product trials and the clinical response or intolerance.
    Step Therapy

    Triptan Nasal-Spray Criteria

    Approve a triptan nasal-spray request when the patient has tried one generic triptan nasal spray or has documented inadequate efficacy or a contraindication with a triptan product.

    • Examples include generic sumatriptan nasal spray and zolmitriptan nasal spray.
    • Document the trial, inadequate response, or contraindication.
    Step Therapy

    Venlafaxine ER Formulation Criteria

    Direct venlafaxine ER tablets to venlafaxine ER capsules. Approve when capsules are non-formulary, when the request is for 225 mg ER tablets, or when the prescriber documents a significant clinical concern preventing capsule use.

    • The capsule-first requirement applies to the 75 mg, 150 mg, and other tablet strengths except the 225 mg tablet exception.
    • Document the formulation issue and clinical impact when requesting an exception.
    Step Therapy

    Meloxicam Formulation NSAID Requirement

    Approve Vivlodex or Zorvolex after five unique prescription-strength oral NSAID trials. OTC NSAIDs count when prescription-strength doses were used.

    • Examples include indomethacin, etodolac, flurbiprofen, ibuprofen, ketoprofen, meloxicam, nabumetone, naproxen, oxaprozin, diclofenac, and piroxicam.
    • Document five distinct NSAIDs and treatment outcomes.
    Step Therapy

    Vyvanse Generic Prerequisite

    Approve brand Vyvanse after a documented trial of generic lisdexamfetamine capsules.

    • Document the generic product, treatment history, response, and any intolerance or adverse reaction.
    Prior Authorization

    Preferred Product First

    Before approving a non-preferred strength, formulation, brand, or dosage form, direct the patient to the preferred product. Approve only when the preferred product is unavailable, non-formulary, or clinically inappropriate and the exception is documented.

    • This rule applies to preferred strengths, formulations, dosage forms, and bioequivalent generics.
    • Document the substitution attempted or considered and the reason it cannot be used.
    Documentation Required

    Trial History and Clinical Response

    Provider documentation must identify every product tried, relevant dates or treatment history, dose when material, clinical response, efficacy, intolerance, adverse reaction, and reason the trial or alternative was insufficient.

    • Use the prescriber's assessment to distinguish inadequate efficacy from significant intolerance.
    • Document current use when a current product satisfies a prerequisite.
    • A requested product generally does not count as its own prerequisite trial.
    Documentation Required

    Formulation and Brand Exception Documentation

    For brand, formulation, strength, or dosage-form exceptions, identify the difference between the requested product and the preferred alternative and explain the clinical impact.

    • Relevant differences may include dyes, fillers, preservatives, or other inactive ingredients.
    • Document the resulting allergy, serious adverse reaction, swallowing limitation, pump incompatibility, or other reason substitution is inappropriate.
    Documentation Required

    Clinical Exception Documentation

    Clinical exceptions require prescriber documentation of the specific contraindication, significant clinical concern, swallowing limitation, visual impairment, pump or meter incompatibility, pregnancy-related concern, or other circumstance preventing use of the preferred product.

    • A general preference is not sufficient.
    • State why the preferred product cannot be used and why the requested product is medically appropriate.
    Denial Risk

    Failure to Meet Market-Event Criteria

    A request is at risk for denial when required trials, product history, clinical response, or exception documentation are missing or when the patient has not first used the preferred strength, formulation, brand, or dosage form.

    • Verify all prerequisite products and required counts before submission.
    • Do not substitute the requested product for a specified prerequisite unless the criteria expressly allow it.
    • Document formulary status when the criteria provide a formulary exception.
    Denial Risk

    Insufficient NSAID Trials

    Requests requiring five NSAID trials may be denied when the record does not establish five unique prescription-strength oral NSAIDs or qualifying OTC use at prescription-strength doses.

    • Count unique NSAID ingredients, not multiple products containing the same ingredient.
    • Document the dose or strength and treatment outcome for each trial.
    Denial Risk

    Unjustified Brand Request

    A brand request may be denied when a preferred bioequivalent generic is clinically appropriate and the prescriber has not documented a qualifying inactive-ingredient difference, allergy, serious adverse reaction, or other applicable exception.

    • The requested brand does not establish medical necessity by itself.
    • Identify the inactive ingredient and the resulting clinical concern.
    Denial Risk

    Explicitly Non-Covered Products

    The following products are explicitly not covered under Market Events and should not be approved through these criteria.

    • Amlodipine 10 mg-celecoxib 200 mg (Consensi).
    • Lidocaine-tetracaine 7%/7% cream.
    • Lorzone (chlorzoxazone) 375 mg tablets.
    • Trinaz tablets.
    Denial Risk

    Requested Product Cannot Satisfy Prerequisite

    A trial of the requested agent does not satisfy a prerequisite when the criteria specify other products. Require the named prerequisite therapies unless a stated formulary or clinical exception applies.

    • Treximet does not count toward the required naproxen and sumatriptan trials.
    • Ketoprofen does not replace the required lactulose oral-solution trial.
    • Use of a requested product does not replace specified NSAID, antihistamine, or other step-therapy products.
    The requested brand generally requires prescriber documentation that an inactive-ingredient difference, such as dyes, fillers, or preservatives, would cause a significant allergy or serious adverse reaction.
    130-Day Look-Back
    Applies toEntresto tablets (brand).
    Look-back period130 days.
    History checkAutomated claims history identifies generic sacubitril-valsartan use within the 130-day look-back period; that history excludes the stated Entresto criteria.
    Contraindication or clinical exception: The prescriber documents a contraindication or significant clinical concern preventing use of the preferred alternative, including an applicable swallowing limitation, device incompatibility, visual impairment, pregnancy-related concern, or other product-specific exception.